ArticleClinical medicine insights. Endocrinology and diabetes2026
Feasibility and Short-Term Outcomes of Radiofrequency Ablation for Low-Risk Papillary Thyroid Carcinoma in an Outpatient Endocrinology Setting in the USA.
Article in Clinical medicine insights. Endocrinology and diabetes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Radiofrequency ablation (RFA) has emerged as a minimally invasive alternative to surgery for selected patients with papillary thyroid carcinoma (PTC). However, North American data on outpatient endocrinologist performed RFA for PTC remains limited. This study evaluated the efficacy and safety of outpatient RFA in a United States outpatient clinic setting. Objective: To evaluate the feasibility, short-term tumor volume response and safety profile in an outpatient RFA for low-risk PTC in a United States outpatient clinic setting. Methods: A retrospective observational study of a non-comparative clinical cohort, conducted on 22 patients, consisting of 18 females and 4 males with cytologically confirmed PTC who underwent single-session outpatient RFA under local anesthesia and mild conscious sedation between 2021 and 2023. RFA was performed using 18-gauge electrodes with a 0.5 cm active tip. Serial ultrasounds were used to assess PTC lesion volume reduction. Results: The mean overall PTC volume reduction at the 12-month mark was 71%. Interval specific longitudinal analysis revealed the following volume reduction rate: 3 months, 27.4% volume reduction; 6 months, 72.5% volume reduction; 9 months, 80.6% volume reduction; and 12 months, 87.5% volume reduction. Average longitudinal VRR for BRAF-positive tumors (n=4) showed a 77.05% mean volume reduction compared to 72.3% in BRAF-negative tumors (n=18). Interval-specific volume reduction in T1a tumors (n=12) revealed: 3 months, 55.4% volume reduction; 6 months, 89% volume reduction; 9 months, 74% volume reduction; 12 months; 89% volume reduction. Whereas volume reduction in T1b tumors (n=9) revealed: 3 months, 60.14% volume reduction; 6 months, 79.5% volume reduction; 9 months, 77% volume reduction; 12-month, 85.66% volume reduction. The single T2 case displayed 19% volume reduction at 3 months and 67% at 9 months follow-up. 3 patients achieved a complete lesion disappearance on ultrasound via extended follow-up of 36 months. Conclusion: This single-centre retrospective cohort represents an initial North American experience of outpatient RFA for ATA low-risk PTC. The findings suggest RFA is a feasible minimally invasive option in appropriately selected patients, demonstrating substantial short-term tumor volume reduction. No early complications were observed in this cohort. However, given the limited sample size, retrospective design, and restricted long-term follow-up, further prospective multicenter studies are required to better define long-term efficacy and oncologic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.